Pharma BD Deal Intelligence
Lilly's up to $2.3 billion bet on Ajax hands it AJ1-11095, a Type II JAK2 inhibitor meant to outlast Incyte's Jakafi in myelofibrosis and polycythemia vera patients who stop responding — though the asset was still only in Phase 1 at signing.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines. Ajax's drug could deliver deeper and…
Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax Therapeutics in a deal worth up to…
Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax. Eli Lilly announced an offer of up to $2.3 billion for clinical-stage Ajax…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Lilly will acquire Ajax Therapeutics in a deal worth up to $2.3B in upfront and contingent milestone payments to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for MF/PV; subject to HSR clearance and customary closing conditions.
160K US cases/yr · $1.2B US Market · ~95% JAK2 V617F mutation prevalence
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal expansion of erythroid (and often myeloid and megakaryocytic) lineages, leading to elevated red cell mass, increased blood viscosity, and elevated risk of thrombotic events (stroke, MI, DVT/PE). Nearly all PV patients carry a JAK2 V617F mutation (~95%) or JAK2 exon 12 mutation, driving constitutive JAK-STAT signaling. Symptoms include pruritus, fatigue, headache, erythromelalgia, and splenomegaly. Disease can transform to myelofibrosis (10-20% at 15-20 years) or acute myeloid leukemia (5-10% at 20 years). Standard of care for low-risk patients is therapeutic phlebotomy plus low-dose aspirin; high-risk patients (age >60 or prior thrombosis) receive cytoreduction with hydroxyurea, PharmaEssentia Besremi (ropeginterferon alfa-2b, the only PV-specific approval), or Jakafi for hydroxyurea-resistant/intolerant disease. Median age at diagnosis is ~65, and prevalence is approximately 44-57 per 100,000 in the US. Unmet need centers on disease modification (preventing transformation), durable hematocrit control without phlebotomy, symptom burden reduction, and options for the substantial subset that fails or cannot tolerate first-line cytoreduction.
PV treatment is layered: phlebotomy plus aspirin for low-risk, then cytoreduction with hydroxyurea (off-patent), PharmaEssentia Besremi (ropeginterferon alfa-2b, FDA-approved 2021), and Incyte Jakafi (second-line post-hydroxyurea). Pipeline competitors include Protagonist/Takeda rusfertide (a hepcidin mimetic that controls hematocrit without phlebotomy, FDA action expected 2026) and multiple selective JAK2 V617F inhibitors in early development. Ajax's AJ1-11095 enters as a Type II JAK2 inhibitor with potential to deepen molecular response by binding the inactive JAK2 conformation - a profile that, if clinically validated, could position it as a disease-modifying option distinct from existing symptom-control agents. Five-to-ten years post-close, the strategic question is whether Lilly can demonstrate AJ1-11095 reduces JAK2 allele burden and thrombotic risk meaningfully versus standard cytoreduction. If yes, the asset could carve out a high-value high-risk PV segment; if not, PV will remain a label expansion rather than primary value driver, with myelofibrosis as the commercial centerpiece.
16K US cases/yr · $1.6B US Market
Myelofibrosis (MF) is a rare, chronic myeloproliferative neoplasm (MPN) characterized by clonal proliferation of hematopoietic stem cells, progressive bone marrow fibrosis, extramedullary hematopoiesis, splenomegaly, anemia, constitutional symptoms (fatigue, night sweats, weight loss), and risk of leukemic transformation. The disease is driven primarily by JAK2 V617F (~50-60% of cases), CALR, and MPL mutations that constitutively activate JAK-STAT signaling. Median age at diagnosis is 65-70 years and median overall survival ranges from under 2 years for high-risk patients to over 10 years for low-risk patients. The standard of care is JAK inhibition led by Incyte/Novartis Jakafi/Jakavi (ruxolitinib), with second-line/refractory options including BMS Inrebic (fedratinib), CTI/SOBI Vonjo (pacritinib) for thrombocytopenic patients, and GSK Ojjaara (momelotinib) for anemic patients. Allogeneic stem cell transplant remains the only curative therapy but is restricted to a minority of fit patients. Unmet need is substantial: most patients lose response to Type I JAK inhibitors within 3-5 years, none of the approved agents meaningfully reverse fibrosis, and disease-modifying therapy remains elusive.
The MF/PV market is anchored by Incyte/Novartis Jakafi/Jakavi (ruxolitinib, ~$2.7B 2024 sales) as first-line standard of care. Second-line and niche-segment competitors include BMS Inrebic (fedratinib, ruxolitinib-failure MF), CTI/SOBI Vonjo (pacritinib, thrombocytopenic MF), and GSK Ojjaara (momelotinib, anemic MF) - all Type I JAK inhibitors that bind the active conformation. The pipeline is crowded with combination strategies (Geron Rytelo telomerase inhibitor, BMS navitoclax BCL-XL, Morphic Holding/Sumitomo TGF-beta) and selective JAK2 V617F inhibitors. Ajax's AJ1-11095 is positioned as the first oral Type II JAK2 inhibitor binding the inactive conformation, designed to deliver deeper, more durable disease control and rescue patients who have lost response to Type I agents. BMO analyst Evan Seigerman noted the asset 'could offer a competitive therapy in MPNs where traditional JAK inhibitors have failed.' Five-to-ten years post-close, Lilly's success will hinge on whether the Phase 1 readout (expected late 2026) supports a differentiated efficacy profile in ruxolitinib-experienced MF and whether subsequent registrational trials position AJ1-11095 as a second-line standard or - more ambitiously - displace ruxolitinib in front-line settings.
Ajax announced first proof-of-concept Phase 1 data for AJ1-11095 (Type II JAK2 inhibitor) will be presented orally at EHA 2026; management cited encouraging safety/efficacy including reductions in driver-mutation VAF within a month of dosing. Deal remained pending HSR clearance at review.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Ajax Therapeutics, Inc. (this deal) | 2026 | $2.3B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Hematology deals